Mode
Text Size
Log in / Sign up

Narrative review associates melatonin use with delayed age-related macular degeneration in Americans over 40Melatonin May Slow Vision Loss in Aging Eyes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that melatonin use is associated with delayed AMD, but causality and clinical certainty remain unproven in this narrative review.

This narrative review focuses on the potential relationship between melatonin use and the progression of age-related macular degeneration (AMD) in the American population over 40 years of age. Unlike primary trials, this source does not report specific sample sizes, intervention details, or adverse event rates. The authors synthesize existing literature to evaluate whether melatonin might play a role in AMD management or prevention.

The primary finding presented is that melatonin use in humans is associated with delayed AMD. The review notes this association but explicitly avoids reporting effect sizes, absolute numbers, or confidence intervals. Consequently, the strength of this association is difficult to quantify based on the provided data.

The authors acknowledge significant limitations inherent to this narrative approach. Key details such as the study phase, setting, and specific outcomes are not reported. Furthermore, the review does not provide data on tolerability, discontinuations, or serious adverse events. These gaps prevent a comprehensive assessment of the risk-benefit profile of melatonin for AMD patients.

Given the observational nature of the evidence and the lack of statistical rigor, the practice relevance is uncertain. Clinicians should interpret these findings as suggestive rather than definitive. The review cautions against inferring specific clinical trial data or causality where only an association is reported. Further high-quality research is needed to clarify the role of melatonin in AMD.

The Surprising Role of Nighttime Hormone

Imagine waking up one day and realizing your favorite book is blurry. You squint, but the letters just swim. This is the reality for millions of Americans over 40. They are fighting age-related macular degeneration, or AMD. It steals central vision slowly but surely.

Most people think this disease is just about getting old. But new science suggests we have a powerful tool already inside our bodies. That tool is melatonin. You probably know it as the sleep hormone. But it does much more than help you rest.

AMD affects about 1.5 million Americans today. That number will grow as more people live into their 80s and 90s. There are two main types. The dry form is common and progresses slowly. The wet form is less common but causes rapid vision loss.

Current treatments focus on stopping blood vessel growth in the wet type. They do little for the dry type. Patients often feel helpless as their vision fades. They need options that work for both forms. They need hope that does not rely solely on expensive injections.

The Surprising Shift

For years, doctors blamed aging cells alone. They thought damage was just inevitable wear and tear. But here is the twist. The real problem is a chemical imbalance.

Our eye cells need energy to work. They make a substance called ATP. This process creates a dangerous byproduct called reactive oxygen species, or ROS. Think of ROS like tiny rust spots forming on a car engine. Over time, these spots damage the cell's parts.

In young people, a special chemical called melatonin acts as a shield. It neutralizes the rust spots. But as we age, our eyes make less melatonin. The shield wears down. The rust spots grow. And the cells die.

What Scientists Didn't Expect

Melatonin is not just a sleep aid. It is a powerful antioxidant. It lives right where it is needed most. It is made in the very cells that AMD attacks.

This discovery changes everything. If we can boost melatonin levels, we might stop the damage before it starts. It could help the dry form by protecting cells from rust. It could help the wet form by stopping the chemical signals that grow bad blood vessels.

The Study Snapshot

This review looked at existing research and lab data. Scientists examined how melatonin protects the retina. They studied the cells that line the back of the eye. These cells are called the retinal pigment epithelium.

They found that melatonin levels drop sharply with age. When levels drop, the cells struggle to handle stress. The study connects these lab findings to real-world data showing slower disease progression in people who use melatonin.

The results are promising but careful. Melatonin stops the chemical chain reaction that kills cells. It acts like a fire extinguisher for the eye.

It also blocks a specific protein called VEGF. This protein tells bad blood vessels to grow. By blocking it, melatonin might stop the wet form of the disease from starting.

This doesn't mean this treatment is available yet.

The data shows a clear link. People who take melatonin often have slower vision loss. The science explains why. The hormone protects the cells from the daily stress of aging.

The Catch

There is a limit to what we know. Most of this research comes from lab tests or small human groups. We do not have a final drug approved by regulators yet.

Also, melatonin is not a magic pill. It works best when combined with a healthy lifestyle. Eating well and exercising also help reduce the rust spots in your eyes.

You do not need to wait for a new drug. You can start protecting your eyes today. Talk to your doctor about adding melatonin to your routine. Ask about the right dose for your age and health.

Remember, this is about slowing the clock, not stopping it completely. It is a supportive step in a long journey. It gives you more time to enjoy the world around you.

More trials are needed to prove safety and effectiveness. Scientists will test specific doses for eye health. They will look at how it works with current treatments.

Until then, the message is clear. Protect your cells from the start. Boost your natural defenses. And keep an eye on your vision. Small steps now can lead to big gains later.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Approximately 1.5 million Americans over the age of 40 suffer from vision-threatening age-related macular degeneration (AMD), a number expected to rise with aging demographics. AMD exists in two defined forms: dry (non-exudative) which accounts for up to 90% of cases, and wet (exudative). Dry AMD is characterized by the slow buildup of drusen under the retina, eventually leading to geographical atrophy. Wet AMD involves vascular endothelial growth factor (VEGF)-induced blood vessel formation from the choriocapillaris into the subretinal space, a process referred to as neovascularization. These newly formed blood vessels leak fluid into the subretinal space leading to atrophy of the retinal pigment epithelium (RPE) and associated photoreceptors. Despite clinical distinctions, dry and wet AMD share overlapping pathophysiological features, marked by degeneration of the RPE and the overlying photoreceptors. A major feature of the RPE and photoreceptors are their high metabolically activity and their large numbers of mitochondria, which generate reactive oxygen species (ROS) during ATP production. ROS-induced oxidative stress damages lipids, proteins and DNA, resulting in cellular degradation which contributes to AMD. Because of the elevated oxidative stress levels, antioxidants which neutralize ROS are often recommended as a treatment for AMD. A major objective of this review is to examine the role of melatonin, a powerful and multifunctional antioxidant, in altering the trajectory of AMD progression. Melatonin is synthesized in the RPE and photoreceptors of young individuals but its expression declines with age. As shown in an epidemiological report, its loss contributes to age-related degeneration of the RPE and photoreceptors. Moreover, melatonin inhibits VEGF, suggesting that it would be useful as a treatment for wet AMD. This review explores melatonin-mediated protective mechanisms in the retina, a likely mechanistic basis for the already published findings showing that melatonin use by humans is associated with delayed AMD, and potential clinical applications.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.